## Prescription Monitoring Program Advisory Council State of Louisiana January 12, 2022

### MINUTES

A meeting of the Louisiana Prescription Monitoring Program (PMP) Advisory Council scheduled to meet on Wednesday, January 12, 2022 at Embassy Suites Hotel, 4914 Constitution Avenue in Baton Rouge, LA 70808, convened at 1:10 p.m. to consider the following:

#### AGENDA

- 1. Call to Order
- 2. Amendments to Council Roster
- 3. Quorum Call
- 4. Call for Additional Agenda Items & Adoption of Agenda
- 5. Consideration of Draft Minutes from Previous Meeting October 13, 2021
- 6. Opportunity for Public Comment
- 7. Review of Program Operations
- 8. Review of Legislative and Regulatory Activity
- 9. New Agenda Items Added During Meeting
- 10. Calendar Notes
- 11. Adjourn

<u>Advisory Council Representatives/Designees present</u>: Lauren Bailey (Vice Chair of PMP-AC, LSMS) chaired the meeting. Also present were Shelly Esnard (LAPA), Malcom Broussard (LBP), Kenyatta Mizell (DEA), Crystal Carter (LPA,), Rachel Smith (LDAA), Dr. Joseph Comaty (LAMP).

<u>Others present</u>: Joe Fontenot, Carlos Finalet, Nerissa Montgomery, and Reshmi Ravindranath, (all LABP). Matt Cross and Grayson Walsh (LIPA). Shelly Dupre (LARP-Louisiana Alliance of Retail Pharmacies').

#### Amendments to Council Roster

Mr. Broussard informed members about the passing of Carl W. Aron on January 5, 2022. Mr. Aron had served as the President of the Board of Pharmacy for 25 years. Marty McKay was elected the new President of the Board of Pharmacy during the November 2021 Board meeting. Mr. Broussard reviewed additional amendments to the Council Roster.

#### Quorum Call

Mr. Broussard called the roll but was unable to establish a quorum as only seven members were present. Eleven members are required by R.S. 40:1055(B) to constitute a quorum. Informational meeting continued but no business could be conducted without the required quorum.

#### Call for Additional Agenda Items & Adoption of Agenda

No additional agenda items introduced; adoption of agenda postponed to April 13, 2022 meeting.

#### Consideration of Draft Minutes from October 13, 2021 Meeting

Approval of minutes was delayed until the April 13, 2022 meeting.

#### **Opportunity for Public Comment**

No public comments.

#### **Review of Program Operation**

Joe Fontenot, Executive Director - Designate, presented statistical information regarding the program to the council. (Attachment 1).

Mr. Fontenot explained since the PMP's inception in 2008, the PMP program experienced its first increase in the annual number of eligible prescription transactions reported to the PMP. The increase is a direct result of the additional reporting requirement of two drugs of concern (promethazine in oral liquid formulations and gabapentin containing products) as of January 20, 2021. There is a continued downward trend in the number of opioid and controlled dangerous substance prescription dispensations to Louisiana patients. Hydrocodone bitartrate/acetaminophen remains the number one

controlled substance prescription dispensed to Louisiana patients since the PMP program began in 2008. Mr. Fontenot noted the therapeutic marijuana recommendations have significantly increased since 2019. The North Shore area is identified as having the greatest concentration of therapeutic marijuana patients. Mr. Fontenot reported that both the AWARxE© and Gateway© searches have increased significantly since 2016 with the greatest increase of searches via the PMP integration component, Gateway©. The LDH - Office of Public Health - Bureau of Community Preparedness grant which currently pays for the Gateway© integration fees will expire in April of 2022. The LDH is working to obtain additional funding for the upcoming year. Mr. Fontenot reported that the amount of law enforcement, prosecutorial officials, and specialty court PMP requests have staggered throughout the years with the 2021 requests culminating with the lowest number of requests to date.

#### **Review of Legislative and Regulatory Activity**

Mr. Broussard reviewed legislative and regulatory proposals which can be located under the Public Library, Rulemaking Activity portion of the Board of Pharmacy website.

#### New Agenda Items Added During Meeting

No new agenda items added.

#### **Calendar Notes**


The Vice-Chair, Lauren Bailey, stated in accordance with the council's current preference for meeting dates, the meeting dates for the calendar year of 2022 will be April 13, July 13, and October 12.


#### Adjournment


With no business conducted, the meeting was adjourned at 1:44 p.m.

Minutes prepared by Nerissa Montgomery and Reshmi Ravindranath, then approved as presented during subsequent Council meeting on April 13, 2022.











2021 Top 10 Controlled Substance Prescriptions Dispensed
to Louisiana Patients by <u>Generic Drug Name</u>


Generic Name	Prescription Count	Number of Dosage Units
hydrocodone bitartrate/acetaminophen	1,590,184	81,424,527
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	1,164,145	52,841,147
alprazolam	922,998	47,972,308
tramadol HCI	662,184	35,132,423
oxycodone HCl/acetaminophen	567,422	33,961,623
zolpidem tartrate	558,429	17,549,571
clonazepam	554,311	28,501,915
lisdexamfetamine dimesylate	439,393	13,288,293
lorazepam	308,263	12,997,851
methylphenidate HCl	262,056	11,616,445


# 2021 Top 10 Controlled Substance Prescriptions Dispensed to Louisiana Patients by **Drug Label Name**

Label Name	Prescription Count	Number of Dosage Units
HYDROCODONE-ACETAMINOPHEN 10-325 MG TABLET	718,848	49,391,426
TRAMADOL HCL 50 MG TABLET	648,358	34,667,455
HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET	451,349	11,598,194
ZOLPIDEM TARTRATE 10 MG TABLET	401,032	12,604,980
HYDROCODONE-ACETAMINOPHEN 7.5-325 MG TABLET	394,204	15,342,767
ALPRAZOLAM 0.5 MG TABLET	385,270	19,224,018
DEXTROAMP-AMPHETAMIN 30 MG TAB	287,100	15,717,245
ALPRAZOLAM 1 MG TABLET	282,486	16,717,786
DEXTROAMP-AMPHETAMIN 20 MG TAB	262,876	14,762,201
CLONAZEPAM 0.5 MG TABLET	254,731	12,186,802











	Number of Providers	Number of	Number of PMP	Number of PMP
	Eligible for PMP Access	Providers <u>with</u>	Requests by	Requests by
	(as of 12/31/2021)	Active PMP Access	Providers through	Providers through
		Privileges (as of	<b>AWARxE®</b>	Gateway®
PMP Healthcare Provider Role		12/31/2021)	During 2021Q4	During 2021Q4
Physician (MD, DO)	13,471	9,045	479,812	4,016,643
Nurse Practitioner (APRN)	4,464	3,519	192,590	456,149
Dentist (DDS)	2,265	1,509	5,728	973
Physician Assistant (PA)	1,171	918	35,279	56,423
Optometrist (OD)	371	160	2	0
Podiatrist (DPM)	165	117	1,533	0
Medical Psychologist (MP)	96	91	8,658	6,096
Medical Intern/Resident	1,590	1,400	16,660	3,560
Prescriber's Delegate	NA	3,381	182,257	0
Pharmacist (PST)	9,549	4,928	951,025	2,014,698
Pharmacist's Delegate	NA	1,509	118,721	0
Totals	33,142	26,577	1,992,265	6,554,542





PMP Interstate Data Sharing through PMP InterConnect®						
As of December 31, 2021, the Louisiana PMP is sharing with 35 PMPs (1 federal district, 1 territory, 1 federal jurisdiction, and 32 states).						
Alaba	ama Alaska	Arizona	Arkansas			
Colora	ado Connectio	cut Delaware	D.C.			
MHS-	-DOD Florida	Georgia	Idaho			
Indiar	na Iowa	Kansas	Maine			
Mass	achusetts Michigan	Minnesota	Mississippi			
Monta	ana Nevada	New Mexic	o North Carolina			
North	Dakota Oklahom	a Pennsylvai	nia Puerto Rico			
Rhode	le Island South Ca	rolina South Dak	ota Tennessee			
Texas	s Virginia	West Virgir	nia.			
				14		

